Literature DB >> 16084548

Quinine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan.

Ishag Adam1, Isam Salih, Mustafa Idris Elbashir.   

Abstract

An observational clinical trial was conducted in New Halfa, eastern Sudan, in November and December 2003. Sixty-two patients with uncomplicated Plasmodium falciparum malaria were treated with oral quinine (10 mg/kg thrice daily for 7 d); 47 (76%) of these patients were followed-up to day 28, and 5 (10.6%) of them appeared to have late treatment failures. The parasitological failures were early R1 in two (4.3%) patients and late R1 in three (6.4%) patients. The reappearance of parasites in three of these five patients were true recrudescences rather than a re-infection, based on genetic evidence. The present results and those of earlier investigations indicate that the response to quinine in this area may be faltering.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084548     DOI: 10.1016/j.trstmh.2005.05.005

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

1.  Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda.

Authors:  Frederick N Baliraine; Samuel L Nsobya; Jane Achan; James K Tibenderana; Ambrose O Talisuna; Bryan Greenhouse; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 2.  Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis.

Authors:  Charles O Obonyo; Elizabeth A Juma
Journal:  Malar J       Date:  2012-01-04       Impact factor: 2.979

Review 3.  Drug-induced hypoglycaemia: an update.

Authors:  Chaker Ben Salem; Neila Fathallah; Houssem Hmouda; Kamel Bouraoui
Journal:  Drug Saf       Date:  2011-01-01       Impact factor: 5.606

4.  In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.

Authors:  Samuel L Nsobya; Moses Kiggundu; Sarah Nanyunja; Moses Joloba; Bryan Greenhouse; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

5.  Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan.

Authors:  Sakina B Elamin; Elfatih M Malik; Tarig Abdelgadir; Ammar H Khamiss; Mamoun M Mohammed; Elderderi S Ahmed; Ishag Adam
Journal:  Malar J       Date:  2005-09-14       Impact factor: 2.979

6.  A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan.

Authors:  Ishag Adam; Mamoun Magzoub; Maha E Osman; Insaf F Khalil; Michael Alifrangis; Khalid A Elmardi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-08-26       Impact factor: 3.944

7.  Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial.

Authors:  Jane Achan; James K Tibenderana; Daniel Kyabayinze; Fred Wabwire Mangen; Moses R Kamya; Grant Dorsey; Umberto D'Alessandro; Philip J Rosenthal; Ambrose O Talisuna
Journal:  BMJ       Date:  2009-07-21

8.  Efficacy of 3-day low dose quinine plus clindamycin versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children (CLINDAQUINE): an open-label randomized trial.

Authors:  Charles O Obonyo; Elizabeth A Juma; Vincent O Were; Bernhards R Ogutu
Journal:  Malar J       Date:  2022-02-02       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.